WO1996005838A2 - Kombinationspräparat zur anwendung bei immunologischen erkrankungen - Google Patents
Kombinationspräparat zur anwendung bei immunologischen erkrankungen Download PDFInfo
- Publication number
- WO1996005838A2 WO1996005838A2 PCT/EP1995/003125 EP9503125W WO9605838A2 WO 1996005838 A2 WO1996005838 A2 WO 1996005838A2 EP 9503125 W EP9503125 W EP 9503125W WO 9605838 A2 WO9605838 A2 WO 9605838A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pentoxifylline
- compound
- combination preparation
- diltiazem
- preparation according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Definitions
- the invention relates to pharmaceutical combination preparations for the treatment of immunological diseases in the broadest sense, which cause different clinical pictures causally or symptomatically.
- These combination preparations are determined by the pharmacological mechanisms of action on which the individual components are based and can be determined by a
- G-proteins subsequently inositol triphosphate (IP 3 ), diacylglycerol (DAG), phosphatidylcholine (PC) or phosphatidylinositol (Pl) can be detected by stimulus-induced activation of phospholipase C or D have arisen and are accompanied by an increase in intracellular free Ca 2 + , while activation of phospholipase A 2 leads to the formation of arachidonic acid derivatives (prostaglandins, leukotrienes), which in turn can trigger their own stimulus with corresponding sequelae via suitable receptors .
- G-proteins inositol triphosphate
- DAG diacylglycerol
- PC phosphatidylcholine
- Pl phosphatidylinositol
- Both Ca 2 + and cAMP thus represent important information transmitters ("second messenger") in the context of signal transduction, the processes which take place intracellularly in the further course, however, being so complex that a general prediction of the resulting cell biological events is impossible. After all, most of the subsequent activation phenomena seem to depend on phosphorylation steps in the cell, which in turn are regulated by corresponding protein kinases or phosphatases.
- PKC Protein kinase C
- DAG Downlink Activated G protein kinase C
- Ca 2 + / calmodulin complex mostly mediates the Ca 2 + effects in the further course (Hidaka et al .: Cell Caicium 1_3_, 465-472 (1992); Kun et al .: Endocrin. Rev. 14, 40-58 (1993)).
- phosphorylation does not have to lead to activation in every case, but can also have inhibitory effects.
- cAMP-dependent protein kinase A counteracts cell activation, just like the complex interplay of Phosphorylation and dephosphorylation allow efficient regulation of cell activity and in this way enable the organism to react sensibly to changing external influences (Sitkovsky et al .: Ann. NY Acad. Sci. 532, 350-358 (1988); Takayama et al .: J. Pharm. Sci. 78, 8-10 (1989)).
- the same substance can have both agonistic and antagonistic effects.
- cAMP inhibits interleukin-2 (IL-2) -induced activation (Friedrich et al .: Eur. J. Immunol.
- PDE phosphodiesterases
- PDE inhibitors have a correspondingly overlapping inhibitory effect; there are, for example, PDE inhibitors such as, for example, theophylline, pentoxifylline or papaverine, which also inhibit very different phosphodiesterases in a very unspecific manner. But even if PDE inhibitors are referred to in the specialist literature as "specific", this merely means a certain preference for a specific isoenzyme family, without it being possible to derive an exclusive claim from this straight away.
- the Ca 2+ / calmodulin-dependent PDE I cleaves both cGMP and cAMP and is inhibited, for example, by phenothiazine, vinpocetine or IBMX.
- the cGMP-stimulable PDE II also cleaves cGMP and cAMP, however, no selective inhibitors are known for this enzyme in contrast to PDE III, which has a similar substrate specificity as PDE II, but can be inhibited by cGMP and a large number of other substances.
- PDE III inhibitors such as cilostamide, milrinone, trequinsin, indolidane or quazinone suggest that there are different inhibitory areas on the PDE III, but also different types of isoenzymes of this PDE family.
- PDE IV which has a strong preference for the hydrolysis of cAMP, can be found in the literature as Ro 201724 and Rolipram, while the PDE V specific for the cleavage of cGMP is inhibited by zaprinast or dipyridamole. Substances that can lower the content of biologically effective intracellular Ca 2+ are also known and are already used therapeutically in many cases.
- dihydropyridines e.g. nifedipine, nicardipine, nimodipine
- phenylalkylamines e.g. verapamil
- benzothiazepines e.g. diltiazem
- Substances that meet these requirements are, for example, ryanodine, dantrolene or TMB-8, but have currently only experimental significance for the investigation of the mechanism of action just like HA1077, which, in addition to the inhibition of intracellular Ca 2+ mobilization, also apparently also has direct Ca 2 + antagonistic effects, which leads to the group of actual calcium antagonists, which either free Ca Capture 2+ ions directly via a specific chelation, such as EGTA and its descendants (overview be i Grynkiewicz et al .: J. Biol. Chem. 260. 3340-3346 (1985)) or act as calmodulin antagonists.
- the latter include the derivatives of naphthalenesulfonic acid W7, W12 and W13, calmidazolium or fluphenazine as well as the group of cyelosporins or tacrolimus, which, however, first have to be bound to intracellular "immunophilins" before they can use the Ca 2+ / calmodulin-dependent enzyme calcineurin ( inhibit a phosphatase) (Liu: Imm ⁇ nol. Today 14, 290-295 (1993)). Combinations of so-called “PDE inhibitors” with so-called “calcium antagonists” in the broadest sense are already known.
- the invention therefore relates to a combination preparation containing at least
- PDE inhibitor a compound which has a phosphodiesterase inhibitory action
- Known compounds with phosphodiesterase inhibitory activity are, for example:
- Compounds that reduce the intracellular content of biologically effective Ca 2+ are, for example:
- Specific Ca 2+ channel blockers (type P-, L-, N-), e.g. dihydropyridines such as nifedipine, nicardipine, nimodipine, NZ-105, S1 1568, amlodipine, felodipine, isradipine or diperdipine, phenylalkylamines such as verapamil, benzothiazepines such as Diltiazem, atypical Ca 2+ channel blockers such as flunarizine, fluspiril, pimozide, fantofarone, nicergoline, cyclandelate or even antibiotics based on aminoglycosides such as neomycin, gentamycin or kanamycin;
- dihydropyridines such as nifedipine, nicardipine, nimodipine, NZ-105, S1 1568, amlodipine, felodipine, isradipine or diperdipine
- Ca 2+ antagonists for example 1, 2-bis (2-aminoethoxyethane) - N, N, N ', N'-tetraacetic acid (EGTA) or HA1077;
- Inhibitors of Ca 2+ release from intracellular stores for example ryanodine, dantrolene, TMB-8 or HA1077; 4.
- Calmodulin inhibitors for example naphthalenesulfonic acid derivatives, calmidazolium, fluphenazine, cyelosporins or tacrolimus.
- Preferred combination preparations contain pentoxifylline and nifedipine, pentoxifylline and diltiazem, pentoxifylline and verapamil or pentoxifylline and cyclosporin A.
- the combination preparation according to the invention is suitable, for example, for the treatment of acute immunological events such as sepsis, allergy, graft-versus-
- Psoriasis atopic dermatitis, asthma, urticaria, rhinitis, uveitis
- the combination preparation according to the invention can also comprise combination packs or compositions in which the constituents are placed next to one another and can therefore be used simultaneously, separately or at different times on one and the same human or animal body.
- the invention further relates to the use of a combination of a compound which has a phosphodiesterase inhibitory action and a compound which reduces the biologically effective intracellular Ca 2+ content for the production of a medicament with a superadditive increase in the immunosuppressive action.
- the invention further relates to a method for producing the combination preparation, which is characterized in that
- the combination preparation according to the invention can be present as a dosage unit in the form of pharmaceutical forms such as capsules (including microcapsules, which generally do not contain any pharmaceutical carriers), tablets (including coated tablets and pills) or suppositories, the capsule material, when using capsules, performing the function of the carrier and Content e.g. can be present as a powder, gel, emulsion, dispersion or solution.
- oral (peroral) formulations with the two active ingredient components 1) and 2) which contain the calculated amounts of the active ingredients together with any desired pharmaceutical carrier.
- An appropriate formulation (suppository) for rectal therapy can also be used.
- Transdermal application in the form of ointments or creams parenteral (intraperitoneal, subcutaneous, intravenous, intraarterial, intramuscular) injection or infusion of solutions or oral application of solutions containing the combinations according to the invention is also possible.
- ointments, pastes, creams and powders can contain the usual carriers, e.g. animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, talc, zinc oxide, milk sugar, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder or mixtures of these substances.
- carriers e.g. animal and vegetable fats, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, talc, zinc oxide, milk sugar, silicic acid, aluminum hydroxide, calcium silicate and polyamide powder or mixtures of these substances.
- the tablets, pills or granules can be produced by customary processes such as pressing, immersion or fluidized bed processes or boiler coating and contain carriers and other customary auxiliaries such as gelatin, Agarose, starch (e.g. potato, corn or wheat starch), cellulose such as ethyl cellulose, silicon dioxide, various sugars such as milk sugar, magnesium carbonate and / or calcium phosphates.
- the coating solution usually consists of sugar and / or starch syrup and usually also contains gelatin, gum arabic, polyvinylpyrrolidone, synthetic cellulose esters, surface-active substances, plasticizers, pigments and similar additives in accordance with the prior art. Any customary flow regulating, lubricating or lubricating agents such as magnesium stearate and release agents can be used to prepare the pharmaceutical forms.
- the preparations preferably have the form of shell / core tablets or multilayer tablets, the active component 2 being in the shell or in the core or in one layer, while the active component 1 is in the core or in the shell or in another Layer.
- the active ingredient components can also be in retarded form or adsorbed on retardation material or included in the retardation material (e.g. those based on cellulose or polystyrene resin, e.g. hydroxyethyl cellulose). Delayed release of the active ingredients can also be achieved by providing the layer or compartment in question with conventional coatings which are insoluble in gastric juice.
- the dosage to be used is of course dependent on various factors such as the living being to be treated (ie human or animal), age, weight, general state of health, the severity of the symptoms, the illness to be treated, any concomitant illnesses (if any) and the type of accompanying treatment with other medicines, or the frequency of treatment.
- the dosages are generally administered several times a day and preferably once to three times a day.
- the amounts of single active ingredient used here are based on the recommended daily dose of the respective single active ingredient and should generally be in the combination preparation from 10% to 100% of the recommended daily dose, preferably from 20% to 80%, in particular 50%.
- the Suitable therapy with the combinations according to the invention thus consists, for example, in the administration of one, two or 3 individual doses of the combination preparations according to the invention consisting of
- the oral dose is generally 30 mg / day for vinpocetine (component 1) and 240 mg / day for diltiazem (component 2).
- peripheral mononuclear cells were obtained from the blood of healthy donors by density gradient centrifugation in Ficoll-Hypaque (Pharmacia, Uppsala). This isolation step separated monocytes and lymphocytes from the other blood components. This PBMC fraction was worked up further in accordance with the requirements of the test batches described below.
- PBMC PBMC
- HBA phythaemagglutinin
- test substances dibutyryl-cAMP (db-cAMP) or nifedipine (Sigma, Kunststoff) were added in concentrations of 0.01 ⁇ M to 100 ⁇ M (final concentration) alone or in combination in HBSS. Incubation was carried out at 37 ° C in 5% CO under light protection. After 20 hours (h) (TNF ⁇ determination), 24 h (IL-2 determination) or 120 h (IFN determination), the cell supernatants were tested for cytokine release. The TNF ⁇ determination was made via the Cytotoxicity to L929 cells and IL-2 was quantified by the proliferation of CTL-L6 cells, while a sandwich ELISA was used to determine IFN.
- Table 1 shows the inhibition of the PHA-induced release of cytokines (TNF ⁇ , IL-2, IFN) from peripheral mononuclear cells by the exogenous addition of membrane-compatible cAMP (dibutyryl-cAMP), a PDE inhibitor (pentoxifylline) and a Ca 2 + -Channel blocker (nifedipine) individually or in combination:
- Nifedipine 10 // mol / 1 36 ⁇ 9 23 ⁇ 11 16 ⁇ 6
- Example 1 shows, using the classic calcium channel blocker nifedipine, that a combination with the phosphodiesterase inhibitor pentoxifylline leads to the formation of various cytokines relevant for the immune response, such as tumor necrosis factor ⁇ (TNF ⁇ ), interleukin-1 (IL-1) or hterferon (IFN ) inhibits superadditive, so that a superadditive immunosuppressive effect of the combination can also be expected for in vivo conditions.
- TNF ⁇ tumor necrosis factor ⁇
- IL-1 interleukin-1
- IFN hterferon
- Example 2 shows the dependence of the inhibition of PHA-induced cytokine formation on the type of the so-called "calcium antagonist” added.
- the experimental test approach corresponded completely to that of Example 1.
- the test substances pentoxifylline, nifedipine, verapamil, diltiazem (Sigma, Kunststoff) were added in final concentrations of 0.01 ⁇ mol to 100 ⁇ mol, for cyclosporin A (Sandoz, Basel) the final concentration range was 5 ng / ml to 50 ng / ml.
- TNF ⁇ was selected as the representative cytokine, the quantification of which was carried out as in Example 1.
- Table 2 shows the percentage inhibition of the PHA-induced release of TNF ⁇ from peripheral mononuclear cells in the presence of various "calcium antagonists" individually or in combination with pentoxifylline.
- Example 2 shows that the nifedipine used in Example 1 is only representative of other so-called “calcium antagonists" and is characterized by e.g. Diltiazem, Verapamil or Cyclosporin A can be replaced.
- the PBMC fraction was fractionated further to obtain pure T lymphocytes.
- Lympho-KWIK-T a mixture of monoclonal Antibodies from anti-monocytes and anti-B cells and complement, together with a mixture of monoclonal anti-NK and anti-monocyte antibodies with Leu 1 1 b (anti-CD16, IgM) and Leu 7 (anti-CD57, IgM) used (One Lambda Inc., Los Angeles, California, USA).
- the isolation and purification of the T lymphocytes from the PBMC fraction was achieved using the following process steps:
- Monocytes are removed by cold agglutination.
- the cells are washed three times and then for 30 minutes at 4 ° C. with the monoclonal anti-NK and anti-monocyte antibody
- the cells are washed once and incubated again with 0.8 ml of Lympho- KWIK-T for 1 hour at 37 ° C.
- the cell preparation thus obtained contained more than 97% T lymphocytes (CD3 +), as determined by flow cytometry.
- T-lymphocytes were in 200 // l culture medium (RPMI 1640, mixed with 10% fetal bovine serum, penicillin and streptomycin) in flat-bottomed microtiter plates with monoclonal anti-CD3 or anti-CD28 antibodies (each because 1 ⁇ g / ml of each of the monoclonal antibodies) and phorbol myristate acetate (PMA; Sigma, Switzerland; 5 g / ml) are incubated in a 5% CO 2 atmosphere at 37 ° C.
- RPMI 1640 mixed with 10% fetal bovine serum, penicillin and streptomycin
- test substances (cyclosporin A 40 nmol / l to 100 nmol / l, pentoxifylline 2 // mol / I to 80 // mol / I, dbcAMP 0.01 // mol / I to 50 / mol / I) were used individually or in Combination added at time 0. After 64 h incubation, the cells were mixed with 1 // Ci 3 H-thymidine, collected 8 h later on glass fiber filters and the incorporated radioactivity was measured in a ⁇ -counter.
- the percentage inhibition of T lymphocyte proliferation by the test substances was based on a control without a test substance, with the deduction of a basal worth without monoclonal antibodies. The mean of 4 parallel approaches was used for the evaluation. Table 3 shows the inhibition of T lymphocyte proliferation by the test substances individually or in combination depending on the type of lymphocyte activation.
- Pentoxifylline 40 // mol / I 21 ⁇ 7 28 ⁇ 8 db-cAMP 0.1, // mol / I 16 ⁇ 6 1 1 ⁇ 6
- Example 3 is proof that pentoxifylline not only acts as a PDE inhibitor by increasing cAMP, but also that it has a cAMP-independent active component. If T-lymphocytes are activated not via the CD3-dependent mechanism, which is both cyclosporin A and cAMP-sensitive, but rather via the alternative CD28-dependent mechanism, pentoxifylline shows similar effects in both cases, although cAMP remains practically ineffective under the latter conditions .
- test substances pentoxifylline and diltiazem, dissolved in 30 ml of polypropylene glycol / ethanol / water (1: 1: 1, v / v), individually or together in a final concentration of 2% (pentoxifylline) and 1% (diltiazem ) in a commercially available creamy skin care product (Nivea lotion) so that the following 4 different preparations were ultimately available:
- Table 4 shows the treatment result for all 4 preparations according to the above-mentioned evaluation score over the course of a 6-week therapy. Table 4:
- Example 4 shows that the combination according to the invention is effective not only in vitro, but also in vivo in humans.
- pentoxifylline so-called “PDE inhibitor”
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT95930441T ATE208620T1 (de) | 1994-08-25 | 1995-08-07 | Kombinationspräparat zur anwendung bei immunologischen erkrankungen |
US08/793,417 US5990103A (en) | 1994-08-25 | 1995-08-07 | Combination preparation for use in immunological diseases |
MX9701385A MX9701385A (es) | 1994-08-25 | 1995-08-07 | Preparacion de producto combinado para usarse en enfermedades inmunologicas. |
DE59509848T DE59509848D1 (de) | 1994-08-25 | 1995-08-07 | Kombinationspräparat zur anwendung bei immunologischen erkrankungen |
SI9530551T SI0777482T1 (en) | 1994-08-25 | 1995-08-07 | Combined preparation for the therapy of immune diseases |
EP95930441A EP0777482B1 (de) | 1994-08-25 | 1995-08-07 | Kombinationspräparat zur anwendung bei immunologischen erkrankungen |
JP8507740A JPH10504550A (ja) | 1994-08-25 | 1995-08-07 | 免疫疾患に使用するための複合製剤 |
AU33829/95A AU697311B2 (en) | 1994-08-25 | 1995-08-07 | Combined preparation for the therapy of immunological diseases |
DK95930441T DK0777482T3 (da) | 1994-08-25 | 1995-08-07 | Kombinationspræparat til behandling af immunsygdomme |
FI970747A FI970747A (fi) | 1994-08-25 | 1997-02-21 | Yhdistelmävalmiste käytettäväksi immunologisissa sairauksissa |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4430128.6 | 1994-08-25 | ||
DE4430128A DE4430128A1 (de) | 1994-08-25 | 1994-08-25 | Kombinationspräparat mit immunsuppressiven, kardiovaskulären und cerebralen Wirkungen |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/357,230 Continuation US6337325B1 (en) | 1994-08-25 | 1999-07-20 | Combined preparation for the therapy of immune diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996005838A2 true WO1996005838A2 (de) | 1996-02-29 |
WO1996005838A3 WO1996005838A3 (de) | 1996-04-11 |
Family
ID=6526515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1995/003125 WO1996005838A2 (de) | 1994-08-25 | 1995-08-07 | Kombinationspräparat zur anwendung bei immunologischen erkrankungen |
Country Status (12)
Country | Link |
---|---|
US (2) | US5990103A (de) |
EP (1) | EP0777482B1 (de) |
JP (1) | JPH10504550A (de) |
AT (1) | ATE208620T1 (de) |
AU (1) | AU697311B2 (de) |
DE (2) | DE4430128A1 (de) |
DK (1) | DK0777482T3 (de) |
ES (1) | ES2162937T3 (de) |
FI (1) | FI970747A (de) |
MX (1) | MX9701385A (de) |
PT (1) | PT777482E (de) |
WO (1) | WO1996005838A2 (de) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003024457A1 (fr) * | 2001-09-11 | 2003-03-27 | Asahi Kasei Kabushiki Kaisha | Composition medicinale pour la prevention ou le traitement des troubles vasculaires cerebraux et de la cardiopathie |
WO2013013052A1 (en) | 2011-07-19 | 2013-01-24 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
WO2013155465A1 (en) | 2012-04-13 | 2013-10-17 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
WO2015160913A1 (en) | 2014-04-18 | 2015-10-22 | Concert Pharmaceuticals, Inc. | Methods of treating hyperglycemia |
EP2963040A1 (de) | 2009-09-02 | 2016-01-06 | Concert Pharmaceuticals Inc. | Substituierte xanthinderivate |
EP3199203A1 (de) | 2008-02-29 | 2017-08-02 | Concert Pharmaceuticals Inc. | Substituierte xanthinderivate |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6294350B1 (en) * | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
EP1110553B1 (de) * | 1998-08-10 | 2013-03-27 | Asahi Kasei Pharma Corporation | Orale zusammensetzungen zur kontrollierten freisetzung von fasudil hydrochlorid |
US6368815B1 (en) * | 1999-03-29 | 2002-04-09 | Warner-Lambert Company | Screening of molecules that inhibit human phosphodiesterase 4A produced by non-recombinant cell lines |
PT1165558E (pt) * | 1999-03-31 | 2004-02-27 | Vernalis Ltd | Derivados de pirimido¬6,1-a|isoquinolina-4-ona |
CA2781858C (en) | 2000-05-12 | 2015-03-31 | Genzyme Corporation | Modulators of tnf-.alpha. signaling |
US7470718B2 (en) * | 2000-10-03 | 2008-12-30 | Albert Einstein College Of Medicine Of Yeshiva University | Method for treating a demyelinating condition |
MXPA04003266A (es) * | 2001-10-05 | 2004-07-08 | Combinatorx Inc | Combinaciones para el tratamiento de desodrdenes inmuno-inflamatorios. |
DE10226420A1 (de) * | 2002-06-13 | 2004-01-15 | Eucro European Contract Research Gmbh & Co Kg | Verfahren zur Behandlung der Artherosklerose |
US8133903B2 (en) * | 2003-10-21 | 2012-03-13 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases |
AU2003286555A1 (en) * | 2002-10-22 | 2004-05-13 | Harbor-Ucla Research And Education Institute | Phosphodiester inhibitors and nitric oxide modulators for treating peyronie's disease, arteriosclerosis and other fibrotic diseases |
DE60335652D1 (de) * | 2002-11-21 | 2011-02-17 | Genzyme Corp | Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung |
ES2371635T3 (es) * | 2002-11-21 | 2012-01-05 | Genzyme Corporation | Combinación de un derivado de diamida y agentes inmunosupresores para inhibir el rechazo de transplantes. |
US20040147534A1 (en) * | 2003-01-23 | 2004-07-29 | Foote Mary Ann | Topical composition and method for treating occlusive wounds |
US20040241234A1 (en) * | 2003-06-02 | 2004-12-02 | Alpharma, Inc. | Controlled release press-coated formulations of water-soluble active agents |
TW200517114A (en) * | 2003-10-15 | 2005-06-01 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
WO2006054536A1 (ja) * | 2004-11-16 | 2006-05-26 | Nippon Shinyaku Co., Ltd. | 尿路結石症治療剤 |
US20060269579A1 (en) * | 2005-05-25 | 2006-11-30 | Musculoskeletal Research Llc | Compositions for treating osteoarthritis |
US7767710B2 (en) * | 2005-05-25 | 2010-08-03 | Calosyn Pharma, Inc. | Method for treating osteoarthritis |
WO2007139753A2 (en) * | 2006-05-22 | 2007-12-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of diseases or conditions associated with increased c-reactive protein, interleukin-6, or interferon-gamma levels |
EP2203174A4 (de) * | 2007-09-19 | 2010-09-29 | Combinatorx Inc | Therapeutische schemata zur behandlung von immunentzündlichen erkrankungen |
WO2009042854A1 (en) * | 2007-09-26 | 2009-04-02 | Musculoskeletal Research Llc | Ion-channel regulator compositions and methods of using same |
NZ586332A (en) * | 2007-12-17 | 2012-07-27 | Zalicus Inc | Therapeutic regimens for the treatment of immunoinflammatory disorders using dipyridamole and prednisolone |
JP2022531154A (ja) * | 2019-04-30 | 2022-07-06 | ジェネロス バイオファーマ リミテッド | 炎症により引き起こされる自己免疫性皮膚疾患を治療するための化合物及びその使用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0234262A1 (de) * | 1986-02-10 | 1987-09-02 | Dr. Rentschler Arzneimittel GmbH & Co. | Arzneimittelkombination |
EP0490181A1 (de) * | 1990-11-30 | 1992-06-17 | Hoechst-Roussel Pharmaceuticals Incorporated | Verwendung von Xanthinen zur Herstellung eines Medikaments mit immunsuppressiver Wirkung |
EP0493682A2 (de) * | 1990-11-30 | 1992-07-08 | Hoechst-Roussel Pharmaceuticals Incorporated | Verwendung von Xanthinen zur Herstellung eines Medikaments, das die Auswirkungen der Allotransplantatreaktion bei Menschen hemmt |
EP0544391A1 (de) * | 1991-09-02 | 1993-06-02 | Teva Pharmaceutical Industries, Ltd. | Zusammensetzungen für lokale Behandlungen von Schuppenflechten und atopischer Dermatitis |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987000047A1 (en) * | 1985-07-02 | 1987-01-15 | Key Pharmaceuticals, Inc. | Method and composition for the treatment of chronic obstructive pulmonary disease |
US5190972A (en) * | 1992-01-27 | 1993-03-02 | The University Of Melbourne | Method of combatting cyclosporine organ toxicity with prostaglandin analogs |
ATE230990T1 (de) * | 1992-03-04 | 2003-02-15 | Cell Therapeutics Inc | Enantiomere hydroxylierte xanthinverbindungen |
EP0639986A1 (de) * | 1992-05-13 | 1995-03-01 | Alcon Laboratories, Inc. | Topischeopthalmische zusammensetzungen, die eine kombination von calcium-antagonisten mit bekannten antiglaukommitteln enthalten |
US5670506A (en) * | 1993-04-05 | 1997-09-23 | Cell Therapeutics, Inc. | Halogen, isothiocyanate or azide substituted xanthines |
-
1994
- 1994-08-25 DE DE4430128A patent/DE4430128A1/de not_active Withdrawn
-
1995
- 1995-08-07 DE DE59509848T patent/DE59509848D1/de not_active Expired - Fee Related
- 1995-08-07 EP EP95930441A patent/EP0777482B1/de not_active Expired - Lifetime
- 1995-08-07 AU AU33829/95A patent/AU697311B2/en not_active Ceased
- 1995-08-07 WO PCT/EP1995/003125 patent/WO1996005838A2/de active IP Right Grant
- 1995-08-07 MX MX9701385A patent/MX9701385A/es not_active Application Discontinuation
- 1995-08-07 PT PT95930441T patent/PT777482E/pt unknown
- 1995-08-07 US US08/793,417 patent/US5990103A/en not_active Expired - Fee Related
- 1995-08-07 AT AT95930441T patent/ATE208620T1/de not_active IP Right Cessation
- 1995-08-07 JP JP8507740A patent/JPH10504550A/ja not_active Abandoned
- 1995-08-07 ES ES95930441T patent/ES2162937T3/es not_active Expired - Lifetime
- 1995-08-07 DK DK95930441T patent/DK0777482T3/da active
-
1997
- 1997-02-21 FI FI970747A patent/FI970747A/fi not_active Application Discontinuation
-
1999
- 1999-07-20 US US09/357,230 patent/US6337325B1/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0234262A1 (de) * | 1986-02-10 | 1987-09-02 | Dr. Rentschler Arzneimittel GmbH & Co. | Arzneimittelkombination |
EP0490181A1 (de) * | 1990-11-30 | 1992-06-17 | Hoechst-Roussel Pharmaceuticals Incorporated | Verwendung von Xanthinen zur Herstellung eines Medikaments mit immunsuppressiver Wirkung |
EP0493682A2 (de) * | 1990-11-30 | 1992-07-08 | Hoechst-Roussel Pharmaceuticals Incorporated | Verwendung von Xanthinen zur Herstellung eines Medikaments, das die Auswirkungen der Allotransplantatreaktion bei Menschen hemmt |
EP0544391A1 (de) * | 1991-09-02 | 1993-06-02 | Teva Pharmaceutical Industries, Ltd. | Zusammensetzungen für lokale Behandlungen von Schuppenflechten und atopischer Dermatitis |
Non-Patent Citations (7)
Title |
---|
AM J CLIN ONCOL, Bd. 17, Nr. 4, August 1994 Seiten 313-316, D.J. STEWART ET AL. 'Addition of Pentoxifylline plus Nifedipine to chemotherapy in patients with Cisplatin-resistant cancers of the lung and other sites.' * |
ANNUAL MEETING OF THE CANADIAN SOCIETY FOR CLINICAL INVESTIGATION AND THE ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA, OTTAWA, ONTARIO, CANADA, SEPTEMBER 11-14, 1992. CLIN INVEST MED, 15 (4 SUPPL.). 1992. A61., REECE D E ET AL 'CHRONIC GRAFT VERSUS-HOST DISEASE CGVHD IN PATIENTS PTS RECEIVING UNRELATED DONOR UD ALLOGENEIC BONE MARROW TRANSPLANTS ALLO BMTS INCIDENCE RISK FACTORS AND OUTCOME' * |
BIOCHEM PHARMACOL, Bd. 33, Nr. 17, 1984 Seiten 2723-2726, K.S. GALDAL ET AL. 'Inhibition of the thromboplastin response of endothelial cells in vitro' * |
FUNDAM CLIN PHARMACOL, Bd. 8, Nr. 1, 16.Februar 1994 Seiten 26-33, B. SARRIA ET AL. 'The Nicardipine-Isoprenaline interaction in human and guinea-pig isolated airways' * |
J CARDIOVASC PHARMACOL, Bd. 18, Nr. 5, 1991 Seiten 761--768, G. BERKENBOOM ET AL. 'Prevention of Cyclosporine A-induced vascular toxicity by Pentoxifylline' * |
THE 9TH INTERNATIONAL CONGRESS OF IMMUNOLOGY;MEETING SPONSORED BY THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS AND THE INTERNATIONAL UNION OF IMMUNOLOGICAL SOCIETIES, SAN FRANCISCO, CALIFORNIA, USA, JULY 23-29, 1995; CONFERENCE PAPER, Seite 852 KHABAR K S A ET AL 'Pentoxifylline selectively potentiates cyclosporin A (CYA)-mediated suppression of mixed lymphocyte cytotoxicity (MLC) among other immunological functions' * |
TRANSPLANT PROC, OCT 1994, 26 (5) P2745-6, UNITED STATES, CARRIER M ET AL 'Effect of pentoxifylline on renal toxicity of cyclosporine: preliminary results.' * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003024457A1 (fr) * | 2001-09-11 | 2003-03-27 | Asahi Kasei Kabushiki Kaisha | Composition medicinale pour la prevention ou le traitement des troubles vasculaires cerebraux et de la cardiopathie |
EP3199203A1 (de) | 2008-02-29 | 2017-08-02 | Concert Pharmaceuticals Inc. | Substituierte xanthinderivate |
EP2963040A1 (de) | 2009-09-02 | 2016-01-06 | Concert Pharmaceuticals Inc. | Substituierte xanthinderivate |
WO2013013052A1 (en) | 2011-07-19 | 2013-01-24 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
WO2013155465A1 (en) | 2012-04-13 | 2013-10-17 | Concert Pharmaceuticals, Inc. | Substituted xanthine derivatives |
WO2015160913A1 (en) | 2014-04-18 | 2015-10-22 | Concert Pharmaceuticals, Inc. | Methods of treating hyperglycemia |
Also Published As
Publication number | Publication date |
---|---|
DE4430128A1 (de) | 1996-02-29 |
DK0777482T3 (da) | 2002-02-18 |
EP0777482A1 (de) | 1997-06-11 |
DE59509848D1 (de) | 2001-12-20 |
AU697311B2 (en) | 1998-10-01 |
US6337325B1 (en) | 2002-01-08 |
FI970747A0 (fi) | 1997-02-21 |
WO1996005838A3 (de) | 1996-04-11 |
JPH10504550A (ja) | 1998-05-06 |
FI970747A (fi) | 1997-02-21 |
US5990103A (en) | 1999-11-23 |
MX9701385A (es) | 1997-05-31 |
AU3382995A (en) | 1996-03-14 |
PT777482E (pt) | 2002-04-29 |
ES2162937T3 (es) | 2002-01-16 |
EP0777482B1 (de) | 2001-11-14 |
ATE208620T1 (de) | 2001-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0777482B1 (de) | Kombinationspräparat zur anwendung bei immunologischen erkrankungen | |
US6190691B1 (en) | Methods for treating inflammatory conditions | |
DE69233648T2 (de) | Verwendung von Galanthaminen zur Linderung von Benzodiazepin-Nebenwirkungen | |
DE69835441T2 (de) | Behandlung von t-helfer zell typ 2 vermittelten immunkrankheiten mit retinoid antagonisten | |
DE60035631T2 (de) | Inhibitoren der Interleukin-4 Produktion | |
DE69833502T2 (de) | Glucocorticoid receptor antagonisten zur behandlung von demenz | |
DE4430127A1 (de) | Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat | |
DE19610955A1 (de) | Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid | |
DE4410997A1 (de) | Pharmazeutische Zubereitungen und Arzneistoffe zur Prävention und Behandlung endothelialer Dysfunktionen | |
DE69725879T2 (de) | VERWENDUNG VON p-AMINOPHENOLDERIVATEN ZUR HERSTELLUNG VON PHARMAZEUTISCHEN ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON NEURODEGENERATIVEN ERKRANKUNGEN | |
US5605927A (en) | Treatment of skin diseases using ginkgolide PAF antagonists | |
EP0937460A2 (de) | Verwendung eines Mittels gegen Durchfall für die Zubereitung eines Medikaments für die Behandlung von Entzündungen | |
JPS62501360A (ja) | 製薬学的に活性な化合物を含有する病気治療剤 | |
DE19858253A1 (de) | Verwendung von Inhibitoren des KQt1-Kanals zur Herstellung eines Medikaments zur Behandlung von Krankheiten, die durch Helminthen und Ektoparasiten hervorgerufen werden | |
EP0867192B1 (de) | Kombinationspräparat zur Anwendung bei Demenz, enthaltend mindestens eine Verbindung die eine Acetylcholinesterase-Hemmwirkung oder muskarinerge Wirkung zeigt und eine Verbindung die den endogenen extrazellulären Adenosinspiegel erhöht | |
EP1137438B1 (de) | Zubereitung mit verbesserter therapeutischer breite, enthaltend nukleotidsyntheseinhibitoren | |
EP0011818B1 (de) | Arzneimittel bzw. pharmazeutische Zusammensetzungen auf der Basis von Aldosteronantogonisten und Diuretica sowie Verfahren zu ihrer Herstellung | |
EP0821960B1 (de) | Verwendung von Xanthinderivaten in Kombination mit einem 5-Isoxazol-4-carbonsäureamid Derivat und/oder einem 2-Cyano-3-hydroxy-crotonsäureamid Derivat zur Modulation der Apoptose | |
DE60221104T2 (de) | Substituierte diarylharnstoffe als stimulatoren der fas-vermittelten apoptose | |
EP0315197B1 (de) | Oral anzuwendende Arzneiform zur einmal täglichen Behandlung der Hypertonie mit Diltiazemhydrochlorid | |
DE60018438T2 (de) | Pharmazeutische und/oder kosmetische zusammensetzungen | |
EP0604830B1 (de) | Verwendung mindestens eines Paf-Antagonisten zur Herstellung eines Arzneimittels zur Behandlung oder Vorbeugung des Hyperinsulinismus | |
DE2755017C2 (de) | ||
EP1275638B1 (de) | Kombinationspräparat zur Therapie von immunologischen Erkrankungen | |
WO2006111296A2 (de) | Darreichungsformen und kombinationsprärate von pyrimidinbiosyntheseinhibitoren zur erzielung zusätzlicher wirkungen auf das immunsystem |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA CN CZ FI HU JP KR MX NO PL RU SI UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA CN CZ FI HU JP KR MX NO PL RU SI UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1995930441 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 970747 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/001385 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08793417 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1995930441 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995930441 Country of ref document: EP |